uPA (urokinase-plasminogen activator) and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction). We hypothesized that putative functional genetic variation in the two genes encoding uPA and uPAR (PLAU and PLAUR respectively) might influence the susceptibility to MI. We genotyped rs4065 [3 -UTR (untranslated region) * 141C > T) and rs2227564 (Pro141Leu) in the PLAU gene as well as rs344781 (− 516T > C) in the PLAUR gene in 633 MI patients and 1237 gender-and age-matched control subjects. Our results showed that the T allele of rs4065 was significantly associated with an increased risk of MI, with an adjusted OR (odds ratio) of 1.38 [95 % CI (confidence interval), 1.07-1.78; P = 0.012) under the dominant model, 1.4 (95 % CI, 1.12-1.75; P = 0.003) under the additive model and 2.5 (95 % CI, 1.15-5.41; P = 0.02) under the recessive model. The findings were then replicated in another independent case-control study including 545 MI patients and 597 control subjects. In conclusion, our results suggest that rs4065 might be a previously unknown genetic risk factor for MI in the Chinese Han population.
INTRODUCTION
MI (myocardial infarction), a complex and heterogeneous disease with a heritability exceeding 50 % [1, 2] , is one of the leading causes of morbidity and mortality both in China and in Western society. After years of research, elucidating the pathogenesis and identifying the subjects at risk of MI are still a major challenge for the medical community. The identification of genetic variants predisposing to MI is essential to improve our knowledge of the mechanisms underlying MI and, on a broader level, to ameliorate cardiovascular disease prevention and pharmacological treatment.
uPA (urokinase-plasminogen activator) and its specific membrane receptor (uPAR), which are expressed in most cell types, have been implicated in a broad spectrum of biological and pathological processes, including chemotaxis, cell adhesion, migration and growth, fibrinolysis, proteolysis, angiogenesis, inflammation, neointima formation, atherogenesis and plaque destabilization [3, 4] , all of which are involved in the pathogenesis of MI.
uPA is a multifunctional serine protease activating growth factors, inducing proteolytic cascades, modulating cytokines, and regulating receptor shedding, cellular phenotypic modulation and protein expression. It has long been identified that uPA expression is increased in atherosclerotic human arteries [5] . Cozen et al. [6] found that macrophage-targeted overexpression of uPA causes accelerated atherosclerosis, coronary artery occlusions and premature death in Apoe −/−
(apolipoprotein E-null) mice. A recent study indicates that the level of uPA expression by macrophages is an important determinant of atherosclerotic lesion growth in Apoe −/− mice [7] . Patients with stable coronary artery disease were found to have higher plasma uPA peptide levels than age-matched healthy subjects [8] . Recent studies have identified the positive association between circulating uPA/uPAR with atherosclerosis in haemodialysis patients [9] and uraemic patients [10] .
Plasma membrane uPAR is a GPI (glycosylphosphatidylinositol)-anchored protein which binds and activates uPA, thus regulating proteolytic activity at the cell surface. In addition, uPAR is a signalling receptor that often does not require its protease ligand or its proteolytic function [3] . uPAR expression is significantly higher in atherosclerotic human arteries [11] , and uPAR content increased progressively with the severity of atherosclerosis in human coronary arteries [12] . Furthermore, increased expression of uPAR affects monocyte adhesion in acute MI [13] . Studies have shown that uPAR is highly expressed in monocyte-derived macrophages [14] and in symptomatic carotid plaques, especially in regions with high macrophage density and ruptured fibrous cap [15] . Gu et al. [16] demonstrated that uPAR plays a key role in promoting macrophage infiltration into the arterial wall.
Taken together, these observations support the genes encoding uPA and uPAR (PLAU and PLAUR respectively) as two attractive candidates in promoting the pathogenesis of MI. To the best of our knowledge, the PLAU gene in the 10q24 region and the PLAUR gene in the 19q13 region have never been studied for associations with MI. However, they have been found to be associated with other diseases involving inflammation, tissue remodelling or extracellular proteolysis. Variant rs4065 ( * 141C > T), which is in the 3 -UTR (untranslated region) of the PLAU gene, has been associated with rheumatoid arthritis [17] , mitral valve prolapse [18] , urolithiasis [19] , atopy [20] and Alzheimer's disease [21] . Variant rs2227564 (Pro141Leu) causes a missense mutation in the kringle domain of uPA protein [22] , which has been shown to decrease the affinity for fibrin, and possibly for other extracellular matrix components, by enhancing the hydrophobicity of the kringle structure [23] . Variant rs2227564 has been associated with asthma [20] , Alzheimer's disease [24, 25] and colorectal cancer [26] . Variant rs344781 (− 516T > C) is in the 5 near region of the PLAUR gene, which has been shown to cause a change in transcriptional activity [27] . Variant rs344781 has been associated with lung cancer [28] .
Using a candidate gene strategy and based on the genetic association with other diseases, we hypothesized that functional variants of the PLAU and PLAUR genes might contribute to the risk of MI. To test this hypothesis, we investigated the association of these variants with MI in a case-control study, and the results were then replicated in a second independent case-control study.
MATERIALS AND METHODS

Subjects
The first study population comprised 1870 unrelated Chinese individuals, including 633 patients suffering from MI and 1237 age-and gender-matched control subjects. MI patients (469 men and 164 women) either visited the inpatient department or were admitted to one of the participating hospitals (FuWai Cardiovascular Hospital, Tongren Hospital and Tianjin Chest Hospital, China). The patients with MI all underwent CAG (coronary angiography) and left ventriculography. Patients with MI were judged by typical ECG changes (Minnesota Code 1.1 or 1.2 in ECG) and by changes in serum enzymes (troponin T, troponin I, creatine kinase-MB, myoglobin, aspartate aminotransferase and glutamate pyruvate transaminase). The diagnosis was confirmed by the presence of a wall motion abnormality on left ventriculography and by identification of the stenosis responsible in any of the major coronary arteries or in the left main trunk by CAG. The control subjects (868 men and 369 women) were either selected from outpatient clinics from patients with various symptoms or from those attending for an annual health check up. Controls all underwent CAG and had no more than 20 % stenosis in major coronary arteries, or were randomly recruited from healthy community-based residents in Xinyang, China. All were free from vascular and cerebral diseases.
The second population comprised 545 MI patients and 597 control subjects recruited following the same inclusion and exclusion criteria as the first population. MI patients were recruited following hospitalization from Tongji Hospital and the Institute of Hypertension (Wuhan, China). Geographically matched controls were randomly recruited from the population by a house-to-house recruitment protocol.
Our study was carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association and was approved by the ethics committee of FuWai Cardiovascular Hospital, Peking Union Medical College, and the participating hospitals. All subjects who participated in the study provided their written informed consent and were self-reported as Han Chinese. All samples were coded to protect donor identity.
Determination of biochemical variables and clinical data collection
Blood samples were collected after a 12-h overnight fast before the cardiovascular procedures. The plasma and cell buffy coat were kept at − 70
• C. Biological variables were determined within 3 months. A complete clinical history was obtained from all subjects. In addition to a history of hypertension, MI and DM (diabetes mellitus), the following vascular risk factors were also recorded: history of vascular disease, cigarette smoking, BMI (body mass index), HDL-C (high-density lipoprotein cholesterol), LDL-C (low-density lipoprotein cholesterol), TC (total plasma cholesterol), and TGs [triacylglycerols (triglycerides)]. Plasma biochemical parameters were assayed using an automatic analyser (Hitachi 7060). Hypertension was defined as the mean of three independent measures of BP (blood pressure) 140/90 mmHg or the use of antihypertensive drugs [29] . DM was diagnosed when the subject had a fasting glucose level 7.0 mmol/l or 11.1 mmol/l at 2 h after oral glucose challenge, or both [30] . Hyperlipidaemia was defined as a TC level of > 5.72 mmol/l or plasma TGs > 1.70 mmol/l. Smoking was defined as a history of smoking > 2 pack-years and/or smoking within the preceding 1 year. BMI (kg/m 2 ) was calculated from measurements of height and weight.
DNA isolation, genetic variants selection and genotyping
Genetic variants in the PLAU and PLAUR genes were retrieved from the HapMap database for the CHB (Chinese Han in Beijing) sample (release no. 24/phaseII November 08, on NCBI B36 assembly). We searched for variants from 1.5 kb upstream to the end of the PLAU gene region (chromosome 10: 75339396-75347260) and the PLAUR gene region (chromosome 19: 48842088-48867842). The percentage coverage of the HapMap variants is subjected to a MAF (minor allele frequency) threshold of 0.05 and an r 2 > 0.8 threshold with pair-wise tagging, using Haploview software (3.31 version). We selected three functional variants, including rs4065 (MAF 0.111) and rs2227564 (MAF 0.356) in the PLAU gene and rs344781 (MAF 0.467) in the PLAUR gene because they have been reported to be associated with diseases. None Genomic DNA was extracted from peripheral blood leucocytes by the FlexiGene DNA Kit (Qiagen) or using the QG-Mini80 workflow with a DB-S kit (FUJIFILM). Genotyping of the first study population was carried out by PCR-RFLP (PCR-restriction-fragment-length polymorphism) analysis. Primers were designed with Oligo 6 software as shown in Table 1 . The resultant PCR products were then digested overnight with restriction enzymes (New England Biolabs) as shown in Table 1 . Samples in the second population were genotyped using a TaqMan ® 7900HT Sequence Detection System. Probe, and primer sequences (Table 2) for this TaqMan ® 5 -nuclease assay were designed by ABI Primer Expression 3.0 software and synthesized by Genecore Biotechnology. Allelic discrimination was measured automatically using Sequence Detection Systems 2.1 software (autocaller confidence level 95 %). Reproducibility of genotyping for each variant was confirmed by bidirectional sequencing in 96 randomly selected samples from the first population and 96 randomly selected samples from the second population, and the reproducibility was 100 %.
Statistical analysis
The distribution of quantitative variables was tested for normality by use of a one-sample Kolmogorov-Smirnov test. Because the TG level was highly skewed, we compared the difference between cases and controls with a non-parametric Mann-Whitney U test. Quantitative variables, including age, BMI, HDL-C, LDL-C and TC, were compared with a one-way ANOVA. A χ 2 test was used to test for qualitative variables, genotype/allele frequencies and Hardy-Weinberg equilibrium of the variants. ORs (odds ratios) and 95 % CIs (confidence intervals) were used to determine the association between the genotypes and the risk of MI. Multivariate unconditional logistic regression was used to estimate ORs and 95 % CIs after adjustment for age, gender, BMI, hypertension history, cigarette smoking, DM history, HDL-C, LDL-C, TC and TG. A two-tailed probability 
(7.4 %)
value of < 0.05 was considered significant. Power to detect a genetic association was estimated using the QUANTO program 4 (Version 1.2.3). Multiple testing was adjusted using Bonferroni correction. Because we tested three variants and for each of the variants we did three tests (dominate, additive and recessive models respectively), a P value of 0.0056 (0.05/9) was considered significant after Bonferroni correction. Analyses were performed with SPSS 11.5 software for Windows.
RESULTS
Characteristics of the subjects
Clinical characteristic of the cases and controls in the first study are shown in Table 3 . Significantly higher BMI, higher levels of TC and TG, lower levels of HDL-C, a higher number of smokers, and a higher incidence of DM were found in the cases compared with controls (all P < 0.01). The characteristics of subjects in the second independent population are shown in Table 4 . MI patients had a higher prevalence of conventional vascular risk factors, including a higher number of smokers, and higher incidences of hyperlipidaemia, hypertension and DM. 
Association of the PLAU and PLAUR gene variants with a risk of MI
The genotype distributions of the three variants are shown in Table 5 for the two populations, and all fulfilled the expectations of the Hardy-Weinberg equilibrium. The genotype frequency of the alleles of the three variants from the HapMap data was similar to ours. Neither rs2227564 nor rs344781 had any association with a risk of MI in both populations. Genotype (CC/CT/TT) analyses of rs4065 in the PLAU gene were conducted for the dominant model (CT + TT compared with CC), additive model (CC compared with CT compared with TT) and recessive model (TT compared with CT + CC). After adjustment for age, gender, BMI, HDL-C, LDL-C, TC, TG, smoking, hypertension and DM with multivariate logistic regression analysis, the association remained with ORs of 1.38 (95 % CI, 1.0-1.78; P = 0.012) under the dominant model, 1.4 (95 % CI, 1.12-1.75; P = 0.003) under the additive model and 2.5 (95 % CI, 1.15-5.41; P = 0.02) under the recessive model (Table 6) , supporting the T allele of rs4065 as an independent risk factor for MI. After Bonferroni correction, rs4065 was still significantly associated with MI under the additive model. The second independent case-control study confirmed the association between rs4065 T allele and the risk of MI (Table 6 ). After adjustment for conventional vascular risk factors with multivariate logistic regression Table 5 Genotype distribution in two case-control studies CC  CT  TT  CC  CT  TT  TT  TC 
DISCUSSION
To the best of our knowledge, the present study is the first to investigate the association between putative functional variants in the PLAU gene and the PLAUR gene with MI. We found that rs4065 in the PLAU gene was associated with an increased risk of MI in the Chinese Han population, whereas rs2227564 in the PLAU gene and rs344781 in the PLAUR gene had no association with MI. After adjustment for conventional vascular risk factors, the association between rs4065 and MI remained significant, suggesting that the contribution of this variant to the risk of MI is independent of conventional vascular risk factors. After Bonferroni correction, the association between rs4065 and MI remains statistically significant under the additive model. To control the potential false-positive associations, we replicated the results in a second case-control study. The rs4065 variant is located in the 3 -UTR of PLAU mRNA, which contains multiple instability-determining regions [31] . Although its functional impact has not yet been studied, it could be hypothesized that the rs4065 variant would modulate PLAU expression at a post-transcriptional level either by directly modifying the stability of the 3 -UTR or by altering its affinity for mRNA-stabilizing factors [32] .
Although several GWAS (genome-wide association studies) for MI have been reported [33] [34] [35] [36] , no association of rs4065 in PLAU with MI was detected. However, none of the GWAS for MI reported results in a Chinese population. According to the HapMap database (release No. 24/phaseII November 08, on NCBI B36 assembly), the frequency of rs4065 T allele was 0.6 for CEU (CEPH Utah residents with ancestry from Northern and Western Europe), 0.125 for JPT (Japanese in Tokyo, Japan), 0.392 for YRI (Yoruba in Ibadan, Nigeria) and 0.111 for CHB, which presents diversity in different ethnic origins. These findings imply that variant rs4065 might have different effects on MI (or other biological and pathological processes) among different ethnic origins of study cohorts. Although GWAS are a powerful tool in the field of complex disease study, it is still difficult to elucidate all of the genetic risk factors for complex diseases, such as MI, by using a few GWAS.
It is a well-known limitation of all association analyses that, in control functional studies, the functional variants cannot be pinpointed. Nevertheless, association findings may provide some indication and guide future functional studies. More detailed mechanistic studies evaluating the relationship between rs4065 and MI are likely to be necessary to better define any relationship between the PLAU/PLAUR genes and the risk of developing MI. Another limitation of association studies is the possible occurrence of false-positive findings. Larger studies or studies more specifically targeting genetically defined groups are also required and might shed some light on the nature or strength of the association between rs4065 and MI. Furthermore, our findings need to be replicated in other nationalities and confirmed with prospective trials.
In conclusion, the results of our present study suggest a contribution of the PLAU gene variant rs4065 to interindividual variability in the risk of MI. The findings might have a use in the future development of approaches for identifying at-risk individuals and providing strategies to optimize treatment for this complex disease.
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